Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies.
Flawless balance sheet with high growth potential.
Share Price & News
How has Nanosonics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OQS's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: OQS exceeded the German Medical Equipment industry which returned 38.3% over the past year.
Return vs Market: OQS exceeded the German Market which returned -0.1% over the past year.
Price Volatility Vs. Market
How volatile is Nanosonics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Nanosonics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: OQS (€4.12) is trading above our estimate of fair value (€3.83)
Significantly Below Fair Value: OQS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OQS is poor value based on its PE Ratio (171.8x) compared to the Medical Equipment industry average (46.3x).
PE vs Market: OQS is poor value based on its PE Ratio (171.8x) compared to the German market (19x).
Price to Earnings Growth Ratio
PEG Ratio: OQS is poor value based on its PEG Ratio (4.6x)
Price to Book Ratio
PB vs Industry: OQS is overvalued based on its PB Ratio (17.9x) compared to the DE Medical Equipment industry average (4.9x).
How is Nanosonics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OQS's forecast earnings growth (37.6% per year) is above the savings rate (0.2%).
Earnings vs Market: OQS's earnings (37.6% per year) are forecast to grow faster than the German market (22.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: OQS's revenue (21% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: OQS's revenue (21% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OQS's Return on Equity is forecast to be low in 3 years time (17.8%).
How has Nanosonics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OQS has high quality earnings.
Growing Profit Margin: OQS's current net profit margins (13.2%) are lower than last year (14.9%).
Past Earnings Growth Analysis
Earnings Trend: OQS's earnings have grown significantly by 32.2% per year over the past 5 years.
Accelerating Growth: OQS's earnings growth over the past year (14.7%) is below its 5-year average (32.2% per year).
Earnings vs Industry: OQS earnings growth over the past year (14.7%) exceeded the Medical Equipment industry 8.2%.
Return on Equity
High ROE: OQS's Return on Equity (10.4%) is considered low.
How is Nanosonics's financial position?
Financial Position Analysis
Short Term Liabilities: OQS's short term assets (A$113.6M) exceed its short term liabilities (A$14.5M).
Long Term Liabilities: OQS's short term assets (A$113.6M) exceed its long term liabilities (A$4.1M).
Debt to Equity History and Analysis
Debt Level: OQS is debt free.
Reducing Debt: OQS has no debt compared to 5 years ago when its debt to equity ratio was 36.6%.
Debt Coverage: OQS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: OQS has no debt, therefore coverage of interest payments is not a concern.
What is Nanosonics's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OQS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OQS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OQS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OQS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OQS's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Michael C. Kavanagh, BSc, MBA (Advanced,) has been the Chief Executive Officer and President of Nanosonics Limited since October 21, 2013 and served as its Managing Director. Mr. Kavanagh served as a S ...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD766.02K) is below average for companies of similar size in the German market ($USD1.48M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
|CEO, President||6.58yrs||AU$1.16m||0.34% A$4.3m|
|CFO & Company Secretary||9.08yrs||AU$567.33k||0.20% A$2.5m|
|Chief Operating Officer||1.17yrs||AU$187.53k||no data|
|Chief Technology Officer||2.25yrs||AU$515.34k||no data|
|Regional President of United States||2.67yrs||AU$659.22k||no data|
|Chief Strategy Officer & Regional President Asia Pacific||1.25yrs||AU$274.55k||no data|
|Chief Marketing Officer||1.33yrs||no data||no data|
|Head of People & Culture||3.17yrs||no data||no data|
|Head of Global Customer Support & Technical Services||no data||AU$202.22k||no data|
|Senior Vice President of Sales - North America||3.58yrs||no data||no data|
Experienced Management: OQS's management team is considered experienced (2.7 years average tenure).
|CEO, President||6.58yrs||AU$1.16m||0.34% A$4.3m|
|Regional President of Europe||0.67yr||no data||no data|
|Non-Executive Deputy Chairman of the Board & Lead Independent Director||2.58yrs||AU$100.00k||0.036% A$448.3k|
|Non Executive Chairman of the Board||13.17yrs||AU$170.00k||6.3% A$79.4m|
|Non-Executive Director||0.42yr||no data||no data|
|Non-Executive Director||18.83yrs||AU$100.00k||0.14% A$1.7m|
|Non-Executive Director||0.83yr||no data||0.0066% A$83.4k|
|Non-Executive Director||3.58yrs||AU$85.00k||0.0065% A$82.1k|
Experienced Board: OQS's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Nanosonics Limited's company bio, employee growth, exchange listings and data sources
- Name: Nanosonics Limited
- Ticker: OQS
- Exchange: DB
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$2.101b
- Listing Market Cap: AU$1.259b
- Shares outstanding: 300.60m
- Website: https://www.nanosonics.com.au
Number of Employees
- Nanosonics Limited
- 14 Mars Road
- Lane Cove
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NAN||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||May 2007|
|OQS||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 2007|
|NNCS.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||May 2007|
|NAN||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||May 2007|
Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company manufactures and distributes the trophon ultrasound probe disinfector, and its associated consumables and accessories for reducing cross-contamination between patients and the spread of healthcare associated infections. It also provides trophon2, an ultrasound probe high level disinfection device; and trophon EPR, a device designed to disinfect intracavity and surface ultrasound probes. In addition, the company offers trophon EPR and trophon2 consumables and accessories, including NanoNebulant, a proprietary disinfectant liquid; trophon chemical indicators; trophon AcuTrace operator cards, medical instrument tags, printers, printer USB cables, printer label rolls, and logbooks; trophon wall mounts, printer wall mounts, carts, and printer cart mounts; trophon companion drying wipes and companion wipes wall mounts; clean ultrasound probe covers; and trophon AcuTrace PLUS activation cards. It operates in North America, Europe, the Middle East, and the Asia Pacific. The company was incorporated in 2000 and is headquartered in Lane Cove, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 21:54|
|End of Day Share Price||2020/05/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.